Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II

RECOMMENDED

Migraine and Headache

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

★ 2 Recommended by Prof. Dr Christian Kamm, Faculty Member

JAMA.

Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM

doi: 10.1001/jama.2019.16711.

RECOMMENDED

Migraine and Headache

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial

★ 1 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache.

Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M, Yu SY, Finnegan M, Severt L, Trugman JM

doi: 10.1111/head.13682.

Migraine and Headache

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II

Cephalalgia

Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L

doi: 10.1177/03331024211000311

Migraine and Headache

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies

Headache.

Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, Yunes-Medina L, Kinchen KS, Tassorelli C

doi: 10.1111/head.13636.

RECOMMENDED

Migraine and Headache

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Lancet.

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB

doi: 10.1016/S0140-

RECOMMENDED

Migraine and Headache

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Neurology.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group

doi: 10.1212/WNL.

Migraine and Headache

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study

Headache

Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC

doi: 10.1111/head.14196

RECOMMENDED

Migraine and Headache

A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

★ 2 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache.

Lombard L, Ye W, Nichols R, Jackson J, Cotton S, Joshi S

doi: 10.1111/head.13835.

Migraine and Headache

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

BMC Neurol.

Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL

doi: 10.1186/s12883-018-1193-2.

Related content

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study

A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine